Cargando…
Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B(100) in patients with T2DM
BACKGROUND: Apolipoprotein B(100) (ApoB(100)) determination is superior to low-density lipoprotein cholesterol (LDL-C) to establish cardiovascular (CV) risk, and does not require prior fasting. ApoB(100) is rarely measured alongside standard lipids, which precludes comprehensive assessment of dyslip...
Autores principales: | Hermans, Michel P, Ahn, Sylvie A, Rousseau, Michel F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601994/ https://www.ncbi.nlm.nih.gov/pubmed/23446247 http://dx.doi.org/10.1186/1475-2840-12-39 |
Ejemplares similares
-
Non-HDL-cholesterol as valid surrogate to apolipoprotein B(100 )measurement in diabetes: Discriminant Ratio and unbiased equivalence
por: Hermans, Michel P, et al.
Publicado: (2011) -
Novel unbiased equations to calculate triglyceride-rich lipoprotein cholesterol from routine non-fasting lipids
por: Hermans, Michel P, et al.
Publicado: (2014) -
log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
por: Hermans, Michel P, et al.
Publicado: (2010) -
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
por: Hermans, Michel P., et al.
Publicado: (2015) -
The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females
por: Hermans, Michel P, et al.
Publicado: (2012)